Sec. 2. National institute of arthritis and musculoskeletal and skin diseases; scleroderma research expansion

103 words·~1 min read·/bill/113/hr/1429/ih/section-2

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

Part B of title IV of the Public Health Service Act ( 42 U.S.C. 284 et seq. ) is amended by adding at the end the following: The Director of NIH may expand, intensify, and coordinate the activities of the National Institutes of Health with respect to scleroderma, with particular emphasis on the following: Research focused on the etiology of scleroderma and the development of new treatment options. Clinical research to evaluate new treatments options. Basic research on the relationship between scleroderma and secondary conditions such as pulmonary hypertension, gastroparesis, Raynaud's phenomenon, Sjögren's Syndrome, and other diseases as determined by the Director. .

Connectionstraces to 1

Traces to 1 document

U.S. Code

Directors of national research institutes
§ 284

Citation graph

cites case law

Sec. 2

National institute of arthritis and musculoskeletal and skin diseases; scleroderma research expansion

U.S.C.§ 284

Cites 1Cited by 0 across 0 sources